诺和诺德(NVO.US)盘前涨逾4% 竞争对手HIMS撤销低价仿制减肥药计划

Core Viewpoint - Novo Nordisk (NVO.US) shares rose over 4% to $49.88 following the news that competitor Hims & Hers Health (HIMS.US) has withdrawn its plans to launch a low-cost generic weight loss drug due to regulatory and legal pressures, alleviating market concerns about the impact of cheap generics on Novo Nordisk's core products [1] Group 1 - Hims & Hers Health's withdrawal from the generic weight loss drug market strengthens Novo Nordisk's competitive position in the GLP-1 drug market [1] - Novo Nordisk announced a stock buyback program with a maximum repurchase amount of 15 billion Danish kroner [1] Group 2 - Novo Nordisk accused Hims of misleading marketing practices that could endanger patient health and well-being, claiming that Hims' products infringe on its patents related to semaglutide [1] - The company has filed a lawsuit in Delaware against Hims, asserting that their weight loss injection products are composite forms of semaglutide [1]